New immune cells and medication for hard-to-treat blood cancers

This trial is testing a newer kind of cancer treatment called CAR-T cell therapy, which uses your own immune cells that have been specially engineered in a laboratory to recognize and fight cancer. Some participants will receive dasatinib, a medication that may help protect against side effects from the engineered cells. The trial is designed for people whose blood cancers (acute lymphoblastic leukemia, non-Hodgkin's lymphoma, or multiple myeloma) have come back after previous treatments or have not responded to standard therapy.

Standard chemotherapy doesn't work well for many people with these aggressive blood cancers, especially if the cancer returns or never goes into remission in the first place. This trial is exploring whether this medication might reduce dangerous side effects from CAR-T cell therapy, making the treatment safer and more effective for patients who have run out of other options.